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A B S T R A C T
Purpose: Oxcarbazepine (OXC) is an effective anticonvulsant used for treatment of partial and
secondarily generalized seizures. However, there is almost no data regarding its effectiveness and
tolerability when used for treatment of status epilepticus (SE).
Methods: We retrospectively identiﬁed all patients who received OXC for treatment of SE in our hospital
between July 2008 and December 2010 in our hospital and analyzed all available data.
Results: We identiﬁed 13 patients (median age 79 years) who were treated with OXC for refractory SE
after failure of ﬁrst- and second-line therapy in our institution. In the majority of patients, etiology was
remote symptomatic (10/13), and semiology was nonconvulsive (10/13). OXC was initiated as third or
later agent in almost all patients after median latency of 81 h with a median maximum daily dose of
1800 mg. OXC was the last drug before SE cessation in 8/13 patients. Relevant hyponatriemia
<125 mmol/l was seen in 3 patients.
Conclusion: OXC may be an effective alternative in refractory SE, but patients need to be monitored
closely for hyponatriemia.
Practice implications: OXC could be used for refractory SE under close electrolyte monitoring when
standard agents fail or are unsuitable.
 2013 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
Contents lists available at ScienceDirect
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Status epilepticus (SE) is a frequent neurological emergency
that requires immediate treatment. Initial treatment consists in
administration of intravenous or intramuscular benzodiazepines
followed by intravenous anticonvulsant drugs such as phenytoin,
valproate or levetiracetam. SE that does not cease after adequate
doses of benzodiazepines and at least one intravenous anticon-
vulsant is labeled refractory SE. Evidence for treatment of
refractory SE is scarce and mainly consists of small prospective
or retrospective series. In clinical practice, patients either receive
one of the other available intravenous anticonvulsants, or are put
into therapeutic coma, or both. If this approach fails, one of the
rescue strategies is to introduce one of the oral anticonvulsants by
nasogastric tube. Topiramate (TPM)1,2 and pregabalin (PGB)3,4
have been used in this situation with some degree of success.
Oxcarbazepine (OXC) has been developed as follow-up
compound of carbamazepine (CBZ) to avoid some of the relevant
disadvantages of CBZ by using a non-oxidative metabolization
pathway in contrast to the cytochrome P450-mediated metabo-
lism of CBZ.5 OXC has been shown to be similarly effective as CBZ
for treatment of partial epilepsies.6 Oxcarbazepine is licensed for* Corresponding author. Tel.: +49 541 405 6501; fax: +49 541 405 6599.
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monotherapy and thus can be maintained in SE patients even when
they are discharged into outpatient setting. Therefore, it is a
potentially valuable candidate for use in refractory SE.
However, as of yet, there are only scarce reports about the use
OXC for treatment of SE. With this study, we intended to document
our experiences with this substance in patients admitted for SE.
2. Methods
Details of patient identiﬁcation and data collection can be found
in.7 In summary, we retrospectively identiﬁed all patients treated
for SE in our hospital between July 2008 and December 2010. Only
the ﬁrst admission of a patient during this time period was
analyzed. For this case series, we searched for all patients who
received oxcarbazepine, carbamazepine or eslicarbazepine during
the course of SE treatment.
The hospital charts were reviewed for sociodemographic data,
etiology, semiology, onset of SE, and discharge. In our hospital, a
standardized SE documentation form is introduced to the patient’s
chart at the time admission. In this simple document, the treating
physician enters the drugs applied, their effect on the seizure
activity, and all adverse phenomena the physician considers as
most likely treatment-related. All original imaging data and EEG
data were reviewed by at least one of the authors. The patients
underwent neurological examination and cranial imaging (CT orvier Ltd. All rights reserved.
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retrospectively based on admission and discharge documentation.
We used the modiﬁed Rankin Scale (mRS), a rating scale regarding
the patient’s disabilities ranging from 0 (no symptoms) to 5 (bed-
ridden, requires constant attention) respectively 6 (death). SE
semiology was deﬁned as ‘generalized convulsive’, ‘loss of
consciousness without major motor symptoms’, ‘aphasic/dyscog-
nitive’, ‘simple motor’ and ‘other simple partial’ (e.g. aura). SE
starting with generalized convulsions was always regarded as
generalized convulsive. A drug was considered as successful for
treatment of SE when no further anticonvulsants were adminis-
tered until cessation of SE. Time of cessation of SE was deﬁned by
the time when the seizure symptoms ceased and the patient
returned to his baseline, or – if in doubt – by the time of the ﬁrst
EEG showing cessation of the electroencephalographic signs of SE.
Equivalent doses of benzodiazepines were calculated according to
established pharmacologic tables8,9: 10 mg diazepam = 1 mg
lorazepam = 0.5 mg clonazepam = 7.5 mg midazolam.
Statistical analysis was performed using OPENSTAT (http://
statpages.org, Version June 2010). Ranked variables were de-
scribed using mean and standard deviation, or median/quartiles
when normal distribution could not be assumed. For univariate
analysis of categorical data, chi-square test and Fisher’s exact test
(2  2 tables) were used. Interval-scaled or ordinal-scaled data
were analyzed with the Mann–Whitney-U-test (comparison of two
groups), or the Kruskal–Wallis test (comparison of three or more
groups).
3. Results
Fourteen patients were identiﬁed who had received oxcarba-
zepine (13 patients) and carbamazepine (1 patient) for treatment
of status epilepticus. To allow for consistent analysis of the data,
we excluded the patient with carbamazepine from further analysis
and focussed on the oxcarbazepine patients only.
The patients (9 men/4 women) had a median age of 79 years.
Etiology was remote symptomatic in 10, with pre-existing epilepsy
in 7 of them. The other patients had an acute symptomatic cause
for the SE. SE semiology was generalized convulsive in 2, simple
motor in 1, aphasic or dyscognitive in 4, and loss of consciousness
only in 6 patients. All patients had clear lateralization of the ictal
discharges in their EEG. In two patients mRS was 0 or 1 before SE
onset, in all other patients mRS before onset was 3 or 4.
Treatment of SE started after a median latency of 1.1 h. Five
patients received the ﬁrst treatment within 10–30 min after
seizure onset. Oxcarbazepine was used in all but one patient in
refractory SE, i.e. after failure of benzodiazepines and at least one
intravenous anticonvulsant in adequate dose (see Table 1). It was
used as third agent in one patient, as fourth agent in 3 patients, as
ﬁfth agent in 4 patients, and as sixth or later agent in the remaining
4 patients. The median latency from SE onset to the ﬁrst
administration of OXC was 81 h, ranging from 22 h to 621 h.
The median ﬁrst dose was 600 mg, the median max. Daily dose was
1800 mg. In 8 (61.5%) of the patients, OXC was the last drug before
SE cessation. SE ceased within 6 h after ﬁrst administration in 2
patients, and after more than 24 h (median: 144 h) in the other
patients. In three patients, OXC-related side effects (hyponatriemia
in all cases) were seen. Minimum sodium serum levels in those
patients were 112 mmol/l, 121 mmol/l and 125 mmol/l respec-
tively. In the ﬁrst two instances, the patients showed disorienta-
tion, agitation and/or somnolence as symptoms of hyponatremia.
In the third case, no distinct symptoms related to hyponatremia
was observed. None of these patients required invasive measures
such as mechanical ventilation, hemodialysis or hemoﬁltration
owing to hyponatriemia, and in none of them did the side effect
result in a prolongation of hospital stay.SE was ﬁnally successfully treated in 11 (79%) of the patients.
Median mRS at discharge was 5. Three of the 13 patients died
during their hospital stay, two of them owing to their severe acute
illness that had caused the SE, the other one owing to a severe
illness independent of etiology or treatment of SE.
4. Discussion
OXC was administered in patients with refractory SE of various
etiologies and clinical presentations. In more than half of them,
OXC was the last drug administered before SE cessation.
Hyponatriemia was the only relevant side effect observed.
If success rate is deﬁned as the proportion of SE patients in
whom seizure activity stops after administration of an anticon-
vulsant drug regardless of the latency between ﬁrst administration
and cessation of epileptic activity, then the success rate of OXC in
this cohort (57%) can be considered as high. In the same patient
population, success rate for the third or later treatment step
(including all substances applied) was mainly below 40%.7
Intravenous lacosamide did not have a higher median success
rate when looking across all case reports and studies, and including
a relevant number of patients in whom lacosamide was used as
ﬁrst- or second-line therapy.10 Topiramate had a higher success
rate of 67% in a large swiss series of patients treated for refractory
SE in an neurointensive care unit.1 In a series from Pittsburgh4 and
in another swiss series,11 success rate was only about 40%. Swisher
and co-workers reported a success rate of 52% for pregabalin.2
However, they included patients with acute repetitive seizures as
well as patients with post-hypoxic SE, and pregabaline was
initiated as second to fourth agent. Therefore, comparison is
difﬁcult. In another series with patients more similar to our
patients,3 pregabalin showed a success rate of slightly less than
50%. Differences between series are most likely owing to different
etiologies, different doses and titration speed of the substances in
question as well as of the concomitant therapies. Therefore,
comparison of success rates across series and substances is hardly
possible.
The majority of our patients were treated for nonconvulsive SE
(as opposed to generalized convulsive SE). In adults, this is the
most frequent SE form.12 In our hospital cohort7 that had similar
distribution of age, etiology and semiology, nonconvulsive
semiology was the only signiﬁcant risk factor associated with
refractoriness. This supports the potential effectiveness of OXC in
SE.
In only 2 patients, response to OXC was seen within a short time
frame (<6 h). In the other patients, response was delayed.
Therefore it is possible that SE could have stopped anyway in
those patients independent of the administration of OXC. However,
enteral administration of anticonvulsants in critically ill patients
results in very different and delayed resorption speed, owing to
changes of gastrointestinal motility and perfusion. Thus, effective
serum (and brain) levels of OXC may have been reached only with
delay of days.
Maximum 10-OH-metabolite level of OXC was relatively low in
some of the patients treated successfully. However, serum level
was not routinely determined at peak or trough level, but could
also come from a later phase days after ﬁrst administration.
Therefore, peak serum level (expected 3–5 h after enteral
administration5) may have been much higher.
Three of 11 patients suffered from relevant hyponatriemia after
OXC administration. This relatively high rate may be explained by
the high prevalence of other risk factors for hyponatriemia in these
patients such as co-administration of diuretics or insufﬁciency of
the neurohormonal axis or both. In addition, our patients were
relatively old which magniﬁes the hyponatremia risk.13 Although
none of the 3 patients required additional invasive treatment
Table 1
Patient characteristics.
Age, gender Etiology mRS at
adm
Awareness
at adm
AED
before
adm
Semiology Latency
SE onset!
treatment
onset
Course of treatment before
OXC (Substance bolus in mg)
Latency
SE-onset
to OXC
OXC Dose
(bolus!max.
in mg)
Maximal
10-OH-
metabolite
serum level
OXC last drug
(latency to
SE cessation)
Adverse
event
related
to OXC
SE ﬁnally
stopped
by . . .
mRS at
disch
77, m Remote
ischemia
3 Coma VPA LOC only 336h LZP 2! LEV 3000!PHT 1500
!VPA 2400
404h 600!1200 n/a No none n/a 5
74, f Acute CNS
inﬂammation
0 Confusion LEV Dyscognitive 0.5h CLZP 0.5! LZP 6! LEV 3000
! LCM 400
139h 600!1200 n/a Yes!51h Hypo-
natriemia
OXC 0
71, m Acute
hemorrhage
4 Coma None Dyscognitive 9h LZP 6! LEV 3000!PHT 1500
! LCM 400!PROP
81h 1800!1800 n/a No None PHB 5
80, f Remote
ischemia
5 Coma None Simple motor 4h LZP 3!PHT 1500! LEV 3000
! LCM 400
67h 900!1800 n/a Yes (n/a) None n/a 5
77, f Remote
ischemia
3 Coma LCM+
Benzo
LOC only 1h LZP 2! LEV 300! LCM 400
!VPA 1200
213h 600!1800 40mg/l Yes!168h None OXC 6
60, m Acute CNS
inﬂammation
3 Somnolence None LOC only 0.5h LZP 2! LEV 3000!PHT 1500
! LCM 400!VPA 1800
50h 600!1800 15.5mg/l Yes!180h None OXC 4
83, m Remote
ischemia
3 Coma None Generalized
convuls.
0.5h LZP 2!PHT 1500!VPA 1800 96h 600!1200 37.1mg/l Yes!144h None OXC 5
82, f Remote
ischemia
4 Sopor None LOC only 0.3h LZP 6! LEV 3000! LCM 400
!PHT 1500!VPA 2400
34.5h 600!1200 11.1mg/l Yes!122.5h None OXC 4
86, f Tumor and
remote
trauma
3 Sopor LEV Simple motor 1.75h LZP 4! LEV 2000! LCM 400 621h 600!1200 30.7mg/l No None PHT 6
80, f Remote
ischemia
4 Awake GBP Dyscognitive 19.25h LZP 1 22h 600!1800 n/a Yes!3h None OXC 4
84, f Remote
ischemia
4 Somnolence None Simple motor 1.2h LZP!2 LEV 2000 49.5h 600!1200 n/a Yes!4h None OXC 4
79, m Acute
encephalitis
0 Somnolence None LOC only 26h LZP 2! LEV 3000! LCM 400
!VPA 3000!PROP!TOP 800
262h 1200!2400 31.4mg/l No Hypo-
natriemia
n/a 6
56, f Acute trauma 3 Somnolence LEV Generalized
convuls.
0.3h MDZ 5! LEV 3000! LCM 400
!VPA 2000
67h 600!1800 11.7mg/l Yes!151h Hypo-
natriemia
OXC 3
adm, admission; disch, discharge; n/a, not applicable; SE, status epilepticus; f, female; m, male; LOC, loss of consciousness; OXC, oxcarbazepine; benzo, benzodiazepine; LCM, lacosamide; LZP, lorazepam; MDZ, midazolam; LEV,
levetiracetam; GBP, Gabapentin; PHT, phenytoin; VPA, valproate; PROP, propofol; TOP, topiramate; mRS, modiﬁed Rankin scale.
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need to be monitored carefully for hyponatriemia.
There are several limitations to this study. First, patient
numbers are rather small. In addition, this is a monocentric series.
Therefore, the results cannot be easily generalized to other
circumstances. We deﬁned ‘successful treatment’ as OXC being
the last substance added before cessation of SE. This is a quite
inclusive deﬁnition in contrast to more conservative deﬁnitions
used in studies regarding intravenously applied substances and
may overestimate the effect of OXC. However, OXC can only be
applied enterally, and is a prodrug of the effective metabolite.
Therefore, less strict criteria may be more adequate for this
substance. Finally, this is a retrospective analysis with all inherent
problems. However, in our center, a standardized SE treatment
documentation is established which helps overcome the usual
diversity of documentation quality.
Literally every report regarding treatment of refractory SE ends
with the call for a large prospective and randomized trial. Until
such data are available, this small dataset could help the treating
physician when choosing between therapy options in this hard-to-
treat patient group.
5. Conclusion
Oxcarbazepin was the last drug before cessation of refractory SE
in more than half of the patients and thus may be an effective
treatment option. However, patients need to be monitored closely
for hyponatremia.
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